Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)

Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigila...

Descripción completa

Detalles Bibliográficos
Autores principales: Corbin, Kimberly S., Breen, William G., Strauss, Jonathan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369349/
https://www.ncbi.nlm.nih.gov/pubmed/32715108
http://dx.doi.org/10.1016/j.ctro.2020.06.013
_version_ 1783560761175441408
author Corbin, Kimberly S.
Breen, William G.
Strauss, Jonathan B.
author_facet Corbin, Kimberly S.
Breen, William G.
Strauss, Jonathan B.
author_sort Corbin, Kimberly S.
collection PubMed
description Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigilant of unexpected toxicities with newly approved therapies.
format Online
Article
Text
id pubmed-7369349
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-73693492020-07-23 Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1) Corbin, Kimberly S. Breen, William G. Strauss, Jonathan B. Clin Transl Radiat Oncol Article Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigilant of unexpected toxicities with newly approved therapies. Elsevier 2020-07-03 /pmc/articles/PMC7369349/ /pubmed/32715108 http://dx.doi.org/10.1016/j.ctro.2020.06.013 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Corbin, Kimberly S.
Breen, William G.
Strauss, Jonathan B.
Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
title Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
title_full Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
title_fullStr Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
title_full_unstemmed Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
title_short Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
title_sort radiation dermatitis in patients treated with concurrent trastuzumab emtansine (t-dm1)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369349/
https://www.ncbi.nlm.nih.gov/pubmed/32715108
http://dx.doi.org/10.1016/j.ctro.2020.06.013
work_keys_str_mv AT corbinkimberlys radiationdermatitisinpatientstreatedwithconcurrenttrastuzumabemtansinetdm1
AT breenwilliamg radiationdermatitisinpatientstreatedwithconcurrenttrastuzumabemtansinetdm1
AT straussjonathanb radiationdermatitisinpatientstreatedwithconcurrenttrastuzumabemtansinetdm1

Ejemplares similares